Compare Emerson Electric Co. (EMR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs GeneDx Holdings Corp — how do they compare? Emerson Electric Co. trades at $162.07 (market cap $88.72B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Emerson Electric Co. is far larger — about 43.9× GeneDx Holdings Corp's market cap, and Emerson Electric Co. pays a 1.4% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and GeneDx Holdings Corp for 19 Days on average.
| EMR | WGS | |
|---|---|---|
Market Cap | $88.72B | $2.02B |
Volume | 2,355,255 | 734,640 |
Sector | Industrials | Health |
52-Week High | $164.38 | $167.51 |
52-Week Low | $123.30 | $34.51 |
Typical Hold Time | 81 Days | 19 Days |
Enterprise Value | $99.80B | $2.05B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.13, up 1.2% today, with a bullish technical trend and strong quarterly earnings beats. The stock is supported by a 53.49% analyst buy consensus and a $165.90 price target. Revenue growth is steady, with 2025 revenue at $18.02B and net income of $2.29B, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. Recent news highlights momentum and Wall Street optimism, though valuation multiples like a P/E of 34.81 suggest premium pricing.
EMR's outlook is positive, driven by earnings momentum and analyst confidence, but risks include elevated valuation and debt levels. The stock offers growth potential with a dividend, yet investors face headwinds from competitive pressures and economic cycles. Upside to the consensus target implies modest gains, balancing fundamental strength with valuation concerns.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
